Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients
Status:
Completed
Trial end date:
2019-03-29
Target enrollment:
Participant gender:
Summary
A prospective, open-label, multicenter Phase-II trial to evaluate the efficacy and safety of
a sequential regimen of Bendamustine followed by GA101 and Ibrutinib followed by Ibrutinib
and GA101 maintenance in CLL patients.